Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Tra
- PDF / 541,825 Bytes
- 20 Pages / 595.276 x 790.866 pts Page_size
- 52 Downloads / 186 Views
ORIGINAL RESEARCH
Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study Treatment pattern and outcomes in patients with multiple myeloma Jianming He
. Luke Schmerold . Rian Van Rampelbergh . Lugui Qiu . Ravi Potluri .
Anandaroop Dasgupta . Lin Li . Yunan Li . Peter Hu . Sepideh Nemat . Steven S. Smugar . Paul Zeltzer . Carlos Appiani . Qing Li . Maneesha Mehra . Ute Richarz Received: August 14, 2020 / Accepted: October 21, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: The objective of this study was to describe the treatment patterns among patients with newly diagnosed multiple myeloma (MM) who had not received autologous stem cell transplantation (ASCT). It further compares the safety and clinical outcomes across different frontline regimens as well as explores whether treatment duration predicts outcomes. Methods: Patients with MM ([ 45 years) who had not received ASCT were retrospectively
Electronic Supplementary Material The online version of this article (https://doi.org/10.1007/s12325020-01546-0) contains supplementary material, which is available to authorized users.
identified from the US SEER-Medicare (Jan 2007–Dec 2016) and Optum (Jan 2007–Sep 2018) databases. Cox proportional hazard models were used to compare overall survival (OS) among bortezomib ? lenalidomide ? dexamethasone regimen (VRd), lenalidomide ? dexamethasone regimen (Rd), cyclophosphamide ? bortezomib ? dexamethasone regimen (CyBorD), bortezomib ? dexamethasone regimen (Vd), and other bortezomib-containing therapies based on propensity score matching. To address immortal time bias, timefixed and time-dependent Cox models were employed to estimate the association of longer frontline treatment exposure with outcomes.
J. He M. Mehra Janssen Global Services LLC, Raritan, NJ, USA
P. Hu Janssen R&D, Raritan, NJ, USA
L. Schmerold R. Potluri A. Dasgupta SmartAnalyst Inc., New York, NY, USA
S. Nemat Janssen R&D, High Wycombe, UK
R. Van Rampelbergh Janssen R&D, Beerse, Belgium
S. S. Smugar P. Zeltzer C. Appiani Q. Li Janssen R&D, Titusville, NJ, USA
L. Qiu Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
U. Richarz (&) Janssen Global Medical Affairs, Cilag, Zug, Switzerland e-mail: [email protected]
L. Li Y. Li Xian Janssen Pharmaceutical Ltd, Beijing, China
Adv Ther
Results: Mean (standard deviation; SD) age was 71 (9.8) years; and 49.51% were women. Bortezomib and lenalidomide-based combinations were the most common treatment modalities. After matching, the HR (95% CI) of OS by frontline therapies comparing VRd with Vd was 0.76 (0.66, 0.86), CyBorD was 0.87 (0.75, 1.05), for other bortezomib-based therapies was 0.56 (0.49, 0.64), Rd was 0.83 (0.73, 0.95), and for other therapies was 0.70 (0.61, 0.80). Longer frontline treatment duration was associated with better OS for overall frontline [HR (95% CI) 0.86 (0.82,
Data Loading...
